

PredicinecfWES


Liquid Biopsy Exome Sequencing

Genome-wide Molecular Insights

Genomic profiling of cell-free DNA (liquid biopsy) using whole exome sequencing (WES) provides insights into genome-wide variation and an unrivaled resolution of structural variations, rearrangements, and exon duplicates.

With Predicine's proprietary next-generation sequencing (NGS) pipeline and increasing affordability of sequencing, genome-wide liquid biopsy analysis enables unprecedented biomarker analysis in clinical trials, treatment monitoring, and acquisition of drug resistance with a single blood draw.

Workflow Flexibility



Input Requirement

5-10ml blood, 2-5ml plasma, or 5-30ng cfDNA

Deliverables

- Tumor fraction & ploidy analysis
- SNV, CNV, Indel and rearrangement
- TMB & MSI

Liquid Biopsy Sequencing

Predicine's comprehensive liquid biopsy sequencing solution offers rapid turnaround time for critical clinical applications. From a single sample, we provide low-pass whole genome sequencing (LP-WGS) data combined with broader coverage using WES and/or in-depth profiling using PredicineCARE or PredicineATLAS focused pan cancer panels, based on tumor fraction from the sample.

LP-WGS information is perfect for screening purpose and allows for informed decision making as to the additional breadth and depth of coverage provided by whole exome or focused pan-cancer panel sequencing.